Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21773965 | 0.84 | MT-CO2 (0.53) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21773973 | 0.83 | MT-CO2 (0.50) | HPGDKMT2AMEN1LMNAMT-CO2 | |
| SCHEMBL2176651 | 0.82 | THRB (0.53) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL21773971 | 0.82 | CA1 (0.57) | KMT2A | |
| SCHEMBL23984534 | 0.80 | HPGD (0.67) | HPGDALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL28667602 | 0.80 | MT-CO2 (0.78) | HPGDKMT2AMEN1LMNAMT-CO2 | |
| SCHEMBL16339006 | 0.78 | HPGD (0.58) | HPGDALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL21773986 | 0.76 | LMNA (0.59) | HPGDKMT2AMEN1LMNA | |
| SCHEMBL6358788 | 0.76 | ALDH1A1 (0.60) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21773970 | 0.75 | MT-CO2 (0.53) | SMN1; SMN2KMT2AMEN1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999677-B2 | Benzylamino-oxoethyl benzamide analogs and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-06-04 | — | — | US | disclosed |
| US-20220162157-A1 | BENZYLAMINO-OXOETHYL BENZAMIDE ANALOGS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-05-26 | — | — | US | disclosed |
| US-20200071264-A1 | BENZYLAMINO-OXOETHYL BENZAMIDE ANALOGS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162157-A1 | BENZYLAMINO-OXOETHYL BENZAMIDE ANALOGS AND METHODS OF USE | BAD, ATP2A1, IAPP | HPGD 1794/4885ALDH1A1 1776/4885SMN1; SMN2 156/4885 |
| US-20200071264-A1 | BENZYLAMINO-OXOETHYL BENZAMIDE ANALOGS AND METHODS OF USE | BAD, ATP2A1, IAPP | HPGD 1794/4885ALDH1A1 1776/4885SMN1; SMN2 156/4885 |
| US-11999677-B2 | Benzylamino-oxoethyl benzamide analogs and methods of use | BAD, ATP2A1, IAPP | HPGD 1794/4885ALDH1A1 1776/4885SMN1; SMN2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.